Phase I

Phase II

Phase III

COVID-19 Therapeutic/Preventative Platform (fully human monoclonal antibodies)


TNX-3600 are fully human monoclonal antibodies generated from SARS-CoV-2+ asymptomatic individuals or COVID-19 convalescent patients, on which Tonix is collaborating with Columbia University. Given the unpredictable trajectory of the SARS-CoV-2 virus and new variants, we seek to contribute to a broad set of monoclonal antibodies, that can be scaled up quickly and potentially combined with other monoclonal antibodies, for the treatment or prophylaxis of SARS-CoV-2 infection. SARS-CoV-2 is the cause of COVID-19.

Learn more here: Platform for Generating Fully Human anti-SARS-CoV-2 Spike Therapeutic Monoclonal Antibodies

TNX-3600 is an investigational new biologic and has not been approved for any indication.